Summary:
Do you have rheumatoid arthritis?
Are you taking a medication called methotrexate?
If so, you could participate in the Boehringer Ingelheim 1297.2 Study, a new clinical research study in rheumatoid arthritis (RA).
The 1297.2 Study is looking at a potential new treatment for RA. The study will evaluate whether the new potential treatment – an investigational medication – is as effective and as safe as an existing, approved treatment, which has been shown to improve some of the symptoms of RA, such as joint stiffness, swelling, and pain.
You may be eligible to participate if you:
- are between 18 and 80 years of age
- have had moderately or severely active RA for at least 6 months
- are taking a medication for your RA called methotrexate
If you choose to take part in the 1297.2 Study, you will be treated, supported, and monitored carefully by a team of experienced doctors and nurses. All of the medications, examinations, and medical care related to the study will be provided to you at no cost.